Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR3 |
Variant | G382R |
Impact List | missense |
Protein Effect | gain of function |
Gene Variant Descriptions | FGFR3 G382R lies within the transmembrane domain of the Fgfr3 protein (UniProt.org). G382R results in increased Fgfr3 protein dimerization and constitutive activation (PMID: 16841094), and has also been shown to inhibit receptor internalization (PMID: 17172848). |
Associated Drug Resistance | |
Category Variants Paths |
FGFR3 mutant FGFR3 act mut FGFR3 G382R |
Transcript | NM_000142.5 |
gDNA | chr4:g.1804398G>C |
cDNA | c.1144G>C |
Protein | p.G382R |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_006713868.2 | chr4:g.1804392G>A | c.1144G>A | p.G382R | RefSeq | GRCh38/hg38 |
XM_006713868 | chr4:g.1804392G>A | c.1144G>A | p.G382R | RefSeq | GRCh38/hg38 |
NM_001354809.2 | chr4:g.1804398G>C | c.1144G>C | p.G382R | RefSeq | GRCh38/hg38 |
XM_006713872 | chr4:g.1804398G>C | c.1144G>C | p.G382R | RefSeq | GRCh38/hg38 |
NM_000142.5 | chr4:g.1804398G>C | c.1144G>C | p.G382R | RefSeq | GRCh38/hg38 |
NM_001163213.2 | chr4:g.1804392G>A | c.1144G>A | p.G382R | RefSeq | GRCh38/hg38 |
XM_006713870 | chr4:g.1804392G>A | c.1144G>A | p.G382R | RefSeq | GRCh38/hg38 |
XM_006713873.2 | chr4:g.1804398G>C | c.1144G>C | p.G382R | RefSeq | GRCh38/hg38 |
NM_000142 | chr4:g.1804398G>C | c.1144G>C | p.G382R | RefSeq | GRCh38/hg38 |
XM_047449821.1 | chr4:g.1804392G>A | c.1144G>A | p.G382R | RefSeq | GRCh38/hg38 |
NM_000142.4 | chr4:g.1804398G>C | c.1144G>C | p.G382R | RefSeq | GRCh38/hg38 |
NM_001354810.2 | chr4:g.1804398G>C | c.1144G>C | p.G382R | RefSeq | GRCh38/hg38 |
XM_047449824.1 | chr4:g.1804398G>C | c.1144G>C | p.G382R | RefSeq | GRCh38/hg38 |
NM_001354809.1 | chr4:g.1804398G>C | c.1144G>C | p.G382R | RefSeq | GRCh38/hg38 |
XM_006713871.1 | chr4:g.1804392G>A | c.1144G>A | p.G382R | RefSeq | GRCh38/hg38 |
XM_047449823.1 | chr4:g.1804398G>C | c.1144G>C | p.G382R | RefSeq | GRCh38/hg38 |
XM_006713869 | chr4:g.1804392G>A | c.1144G>A | p.G382R | RefSeq | GRCh38/hg38 |
XM_006713869.2 | chr4:g.1804392G>A | c.1144G>A | p.G382R | RefSeq | GRCh38/hg38 |
XM_011513420.2 | chr4:g.1804398G>C | c.1144G>C | p.G382R | RefSeq | GRCh38/hg38 |
XM_006713868.1 | chr4:g.1804392G>A | c.1144G>A | p.G382R | RefSeq | GRCh38/hg38 |
XM_006713869.1 | chr4:g.1804392G>A | c.1144G>A | p.G382R | RefSeq | GRCh38/hg38 |
XM_006713873 | chr4:g.1804398G>C | c.1144G>C | p.G382R | RefSeq | GRCh38/hg38 |
XM_011513422.2 | chr4:g.1804398G>C | c.1144G>C | p.G382R | RefSeq | GRCh38/hg38 |
XM_006713871 | chr4:g.1804392G>A | c.1144G>A | p.G382R | RefSeq | GRCh38/hg38 |
XM_006713871.2 | chr4:g.1804392G>A | c.1144G>A | p.G382R | RefSeq | GRCh38/hg38 |
XM_047449822.1 | chr4:g.1804398G>C | c.1144G>C | p.G382R | RefSeq | GRCh38/hg38 |
XM_006713870.1 | chr4:g.1804392G>A | c.1144G>A | p.G382R | RefSeq | GRCh38/hg38 |
XM_011513420 | chr4:g.1804398G>C | c.1144G>C | p.G382R | RefSeq | GRCh38/hg38 |
XM_011513420.1 | chr4:g.1804398G>C | c.1144G>C | p.G382R | RefSeq | GRCh38/hg38 |
XM_047449820.1 | chr4:g.1804392G>A | c.1144G>A | p.G382R | RefSeq | GRCh38/hg38 |
XM_011513422 | chr4:g.1804398G>C | c.1144G>C | p.G382R | RefSeq | GRCh38/hg38 |
NM_001354810.1 | chr4:g.1804398G>C | c.1144G>C | p.G382R | RefSeq | GRCh38/hg38 |
NM_001163213.1 | chr4:g.1804392G>A | c.1144G>A | p.G382R | RefSeq | GRCh38/hg38 |
XM_011513422.1 | chr4:g.1804398G>C | c.1144G>C | p.G382R | RefSeq | GRCh38/hg38 |
NM_001163213 | chr4:g.1804392G>A | c.1144G>A | p.G382R | RefSeq | GRCh38/hg38 |
XM_006713873.1 | chr4:g.1804398G>C | c.1144G>C | p.G382R | RefSeq | GRCh38/hg38 |
XM_006713870.2 | chr4:g.1804392G>A | c.1144G>A | p.G382R | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|